ArticleAmerican journal of translational research2024
Next-generation sequencing uncovers crucial mutated genes and potential therapeutic targets in ovarian cancer patients.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOvarian cancer is a highly lethal gynecological malignancy, often diagnosed late, resulting in high mortality. While BRCA1 and BRCA2 mutations are known risk factors, the broader genetic landscape needs comprehensive profiling to identify additional diagnostic markers or therapeutic targets. The current study aims to explore the genetic landscape of various cancer-susceptible genes in ovarian cancer patients.
methodsThe genetic landscape of ovarian cancer was investigated by analyzing 27 genes via next-generation sequencing (NGS) in 50 ovarian cancer patients.
resultsMutations were detected in four genes: Breast Cancer 1 (BRCA1) (62%), Cyclin-Dependent Kinase 4 (CDK4) (58%), MutS Homolog 2 (MSH2) (48%), and Phosphatase and Tensin Homolog (PTEN) (22%). Pathogenic mutations were identified in BRCA1 (p.Tyr1853Ter and p.Gln1848Ter), CDK4 (p.Arg24His), and PTEN (p.Tyr29Ter), occurring in 11 patients. Interestingly, these pathogenic mutations were absent in The Cancer Genome Atlas (TCGA) dataset and the gnomAD for the Asian population, suggesting their unique presence in the Pakistani cohort. Functional assays revealed that these mutations significantly reduced the mRNA and protein expression levels of BRCA1, CDK4, and PTEN, as demonstrated by Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) and Immunohistochemistry (IHC) analyses. Receiver Operating Characteristic (ROC) curve analysis confirmed the potential of these genes as biomarkers, with downregulated expression accurately distinguishing between normal and cancerous tissues. Structural validation of mutated proteins using Ramachandran plots and Protein Structure Analysis (ProSA-web) analysis confirmed the stability of the mutations. Drug prediction and molecular docking identified Resveratrol as a potential therapeutic agent, indicating strong binding affinities with BRCA1, CDK4, and PTEN proteins.
conclusionThese findings provide novel insights into the genetic underpinnings of ovarian cancer in the Pakistani population and suggest potential targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.